Carroll Financial Associates’s CRISPR Therapeutics CRSP Stock Holding History

Carroll Financial Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$17K	Hold	225	–	–	﹤0.01%	1013
2021 Q3	$25K	Hold	225	–	–	﹤0.01%	938
2021 Q2	$36K	Sell	225 -494	-69%	-$60.1K	﹤0.01%	901
2021 Q1	$87K	Sell	719 -31	-4%	-$4.68K	0.01%	604
2020 Q4	$114K	Hold	750	–	–	0.01%	491
2020 Q3	$62K	Sell	750 -150	-17%	-$13.3K	﹤0.01%	597
2020 Q2	$66K	Buy	900 +450	+100%	+$26.3K	0.01%	583
2020 Q1	$19K	Hold	450	–	–	﹤0.01%	787
2019 Q4	$27K	Hold	450	–	–	﹤0.01%	800
2019 Q3	$18K	Hold	450	–	–	﹤0.01%	854
2019 Q2	$21K	Hold	450	–	–	﹤0.01%	810
2019 Q1	$16K	Hold	450	–	–	﹤0.01%	802
2018 Q4	$15K	Hold	450	–	–	﹤0.01%	742
2018 Q3	$19K	Hold	450	–	–	﹤0.01%	714
2018 Q2	$26K	Hold	450	–	–	﹤0.01%	614
2018 Q1	$20K	Hold	450	–	–	﹤0.01%	668
2017 Q4	$10K	Hold	450	–	–	﹤0.01%	822
2017 Q3	$8K	Hold	450	–	–	﹤0.01%	858
2017 Q2	$7K	Hold	450	–	–	﹤0.01%	905
2017 Q1	$9K	Buy	+450	New	+$8.84K	﹤0.01%	856

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Carroll Financial Associates's CRSP Position: Q4 2021 in Review

Carroll Financial Associates held its CRISPR Therapeutics (CRSP) position steady in Q4 2021 at 225 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1013.

Carroll Financial Associates first reported a position in CRSP in Q1 2017 and has held it in 20 quarters since. The position peaked at $114K in Q4 2020. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

Carroll Financial Associates held 225 shares of CRISPR Therapeutics worth $17K as of Q4 2021.
Carroll Financial Associates left its CRISPR Therapeutics share count unchanged in Q4 2021.
CRISPR Therapeutics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1013 holding.
Carroll Financial Associates first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 20 quarters since.
Carroll Financial Associates's CRISPR Therapeutics position peaked at $114K in Q4 2020.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.